Cabotegravir-Hormone PK/PD Interactions for HIV Prevention

Abroad (travel likely)RecruitingPHASE1

Conditions

HIV · Prophylaxis · Injectable

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Johns Hopkins School of Medicine, Drug Development Unit, Baltimore, Maryland, United States
Contact: Study coordinator (Pooja Akoijam) · pakoija1@jh.edu · 410-955-1201
Contact: Study coordinator (Deya Chatterji) · dchatte5@jh.edu · 4109551218

Study leads

Mark A Marzinke
Principal Investigator
Johns Hopkins School of Medicine

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

PathToScale: The PERSIST Trial

Oral Pre-exposure Prophylaxis (PrEP) · Long-acting Injectable Cabotegravir for PrEP

Abroad (travel likely)Recruiting

Lilongwe, Malawi

Predictors of Health Service Utilizations Among Key Population in Washington DC

Pre-exposure Prophylaxis · HIV · Health Behavior

Abroad (travel likely)Recruiting

Washington D.C., United States

Vienna HIV Infection Via Sex Study

HIV Infections · HIV Pre-Exposure Prophylaxis · Sexually Transmitted Diseases

Abroad (travel likely)Recruiting

Vienna, Austria

Inhibiting the Anti-apoptotic Factor, BCL-2, at the Time of ART Initiation to Promote Apoptosis of HIV-infected Cells and Restrict the Seeding of the HIV Reservoir (The INITIATE Study)

HIV-1

Abroad (travel likely)RecruitingPHASE1

Aarhus, Denmark · Badalona, Spain